ALDEA Pharmaceuticals
ALDEA Pharmaceuticals develops small-molecule modulators of the ALDH family for the treatment of toxic aldehyde-related diseases.
Launch date
Market cap
-
Enterprise valuation
€87—131m (Dealroom.co estimates Aug 2014.)
Redwood City California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $4.5m | Debt | |
| N/A | $2.0m | Early VC | |
| N/A | $11.5m | Series A | |
$24.0m | Series B | ||
| Total Funding | €34.1m | ||
Related Content
Recent News about ALDEA Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.